降级(电信)
脂肪酶
化学
生物化学
单克隆抗体
水解
脂蛋白脂酶
色谱法
溶解度
重组DNA
食品科学
酶
抗体
生物
有机化学
电信
计算机科学
基因
免疫学
作者
Sisi Zhang,Caterina Riccardi,Douglas E. Kamen,J.J. Reilly,John Mattila,Hanne Bak,Hui Xiao,Ning Li
标识
DOI:10.1007/s11095-021-03160-3
摘要
PurposePolysorbates (PS) are excipients used in the biotech industry to stabilize monoclonal antibody (mAb) protein products. However, PS in drug product formulations can be degraded during storage and lead to particle formation because of the limited solubility of the free fatty acids released through the enzymatic hydrolysis of PS—a process driven by residual host cell proteins, especially lipases, that are co-purified with the drugs. When multiple lipases are present, it is very difficult to know the cause for PS degradation. In this study, we aim to determine the cause of PS degradation from two lipases, lysosomal acid lipase (LAL) and lipoprotein lipase (LPL).MethodsPS degradation pattern of the drug product was compared with those induced by recombinant lipases. Correlations between the concentration of LPL or LAL and PS20 loss were compared. Specific inhibitors, LAL inhibitor lalistat2 and LPL inhibitor GSK264220A, were used to differentiate their degradation of PS in the drug products.ResultsThe complete inhibition of PS20 degradation by lalistat2 suggested that LAL, rather than LPL, was responsible for the PS20 degradation. In addition, LAL was more strongly correlated than LPL with the percentage of PS20 degradation. No PS20 degradation was observed for several mAbs containing similar levels of LPL (0.5–1.5 ppm) in the absence of LAL, suggesting that LPL concentrations below 1.5 ppm does not degrade PS20 in drug products.ConclusionsLAL was determined to be the cause of the PS20 degradation. This study provides a practical strategy to determine the root cause of PS degradation.
科研通智能强力驱动
Strongly Powered by AbleSci AI